WO2001064743A1 - CONSTRUCTION A LIAISON GPib-LIPIDE ET UTILISATION CORRESPONDANTE - Google Patents
CONSTRUCTION A LIAISON GPib-LIPIDE ET UTILISATION CORRESPONDANTE Download PDFInfo
- Publication number
- WO2001064743A1 WO2001064743A1 PCT/JP2001/001635 JP0101635W WO0164743A1 WO 2001064743 A1 WO2001064743 A1 WO 2001064743A1 JP 0101635 W JP0101635 W JP 0101635W WO 0164743 A1 WO0164743 A1 WO 0164743A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- conjugate
- gpib
- complex
- pao
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 claims abstract description 151
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 11
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 229940127218 antiplatelet drug Drugs 0.000 claims abstract description 6
- 230000003966 vascular damage Effects 0.000 claims abstract description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 22
- 125000000524 functional group Chemical group 0.000 claims description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 102100036537 von Willebrand factor Human genes 0.000 claims description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 14
- 229930195729 fatty acid Natural products 0.000 claims description 14
- 239000000194 fatty acid Substances 0.000 claims description 14
- 150000004665 fatty acids Chemical class 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 14
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229930186217 Glycolipid Natural products 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000003172 aldehyde group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 4
- 108010081391 Ristocetin Proteins 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 229940030225 antihemorrhagics Drugs 0.000 claims description 4
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 claims description 4
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- 239000002874 hemostatic agent Substances 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 150000002497 iodine compounds Chemical class 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 230000005298 paramagnetic effect Effects 0.000 claims description 4
- 229950004257 ristocetin Drugs 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 229960000103 thrombolytic agent Drugs 0.000 claims description 4
- 208000019553 vascular disease Diseases 0.000 claims description 4
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 229960001134 von willebrand factor Drugs 0.000 claims description 3
- 230000004931 aggregating effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- 102000003886 Glycoproteins Human genes 0.000 abstract description 4
- 108090000288 Glycoproteins Proteins 0.000 abstract description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 3
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 229960004676 antithrombotic agent Drugs 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract description 2
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 230000002885 thrombogenetic effect Effects 0.000 abstract 1
- 231100000216 vascular lesion Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 description 23
- -1 GPIIIb Proteins 0.000 description 22
- 208000024248 Vascular System injury Diseases 0.000 description 10
- 208000012339 Vascular injury Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000032 diagnostic agent Substances 0.000 description 6
- 229940039227 diagnostic agent Drugs 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 150000001841 cholesterols Chemical class 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 229910052692 Dysprosium Inorganic materials 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 229910052689 Holmium Inorganic materials 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- WREDNSAXDZCLCP-UHFFFAOYSA-N methanedithioic acid Chemical compound SC=S WREDNSAXDZCLCP-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920003192 poly(bis maleimide) Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- DVUZQONFTJKFPV-UHFFFAOYSA-N pyrrole-2,5-dithione Chemical compound S=C1NC(=S)C=C1 DVUZQONFTJKFPV-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical group NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 101710126496 Envelope glycoprotein I Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- OIRFJRBSRORBCM-UHFFFAOYSA-N Iopanoic acid Chemical compound CCC(C(O)=O)CC1=C(I)C=C(I)C(N)=C1I OIRFJRBSRORBCM-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical group CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 102100031574 Platelet glycoprotein 4 Human genes 0.000 description 1
- 101710202087 Platelet glycoprotein 4 Proteins 0.000 description 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 1
- 101710191888 Platelet glycoprotein IX Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- FFINMCNLQNTKLU-UHFFFAOYSA-N adipiodone Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FFINMCNLQNTKLU-UHFFFAOYSA-N 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002631 carbazochrome Drugs 0.000 description 1
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000003959 coumarin anticoagulant Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- OJSUWTDDXLCUFR-YVKIRAPASA-N deoxy-bigchap Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@H](O)C1 OJSUWTDDXLCUFR-YVKIRAPASA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
- 229960004901 iodamide Drugs 0.000 description 1
- 229940029355 iodipamide Drugs 0.000 description 1
- 229960002979 iopanoic acid Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Chemical class 0.000 description 1
- 239000005017 polysaccharide Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- HNDXKIMMSFCCFW-UHFFFAOYSA-N propane-2-sulphonic acid Chemical compound CC(C)S(O)(=O)=O HNDXKIMMSFCCFW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960000747 sodium estrone sulfate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention includes a conjugate in which GPIb and a lipid are bonded via a polyalkylene oxide (hereinafter, also referred to as a “GPIb-lipid conjugate”), this conjugate, and free lipid.
- the present invention relates to a lipid complex and its use.
- glycoproteins are present on the platelet membrane surface and are involved in the expression of platelet function.
- GPIb, GPIIb, GPIIIa, GPIIIb, GPIV, GPIX and the like are known as such platelet membrane glycoproteins.
- GP Ib functions as a receptor for von Willebrand factor (hereinafter “vWF”).
- vWF von Willebrand factor
- GPI b is a heterodimer with a molecular weight of 160,000 and a disulfide bond between the heavy chain and the /? Chain (Pro c. At l. Acad. Sci. USA, 84, 5615-5619). 1987, Hematology and Oncology, Vol. 31, No. 1, pages 5-10, 1995, etc.).
- VWF plays an important role as an adhesive protein in the formation of platelet thrombus, and at this time, GPIb binds to vWF as a receptor, and the subsequent adhesion of platelets via vWF at the vascular injury site. It is thought to have a function to activate or promote the aggregation reaction.
- the binding between vWF and GPlb has been implicated in the formation of pathological thrombi as well as in the function of hemostasis in injured blood vessels. Therefore, GPIb is expected to be effectively used in examination and diagnosis of vascular injury sites, detection of pathological thrombus, and furthermore, treatment.
- the present inventors proceeded with research in consideration of the above circumstances, and as a result, by introducing a polyalkylene oxide (hereinafter referred to as “PAO”) between GPIb and a lipid, the blood was further reduced.
- PAO polyalkylene oxide
- the present inventors have found that a GPI b-lipid conjugate having excellent storage properties can be prepared, and as a result of further intensive studies, the present invention has been completed.
- the present invention is a.
- the conjugate of (5) above, wherein the lipid having a functional group is a phospholipid, a glycolipid, a fatty acid, glyceride, cholesterol, or an amphipathic lipid;
- GP Ib lipid complex (12) a complex containing GPI b—lipid conjugate and free lipid (hereinafter also referred to as “GP Ib lipid complex”);
- test or diagnostic agent comprising a labeling substance and the complex of (12) as active ingredients
- the labeling substance is a radioisotope, a paramagnetic metal for MRI, an iodine compound for X-ray imaging, a fluorescent substance or a dye,
- a drug-containing composition comprising a drug and the complex of the above (12) as active ingredients; (24) a drug which is a hemostatic agent, a vasoconstrictor, an anti-inflammatory agent, a thrombolytic agent, an anticoagulant or an antiplatelet
- the invention relates to the drug-containing composition according to the above (23), which is an agent. The details of the present invention are described below.
- the GPIb-lipid conjugate of the present invention is a conjugate in which (1) GPlb and (2) lipid are bonded via (3) PAO.
- GPIb used in the present invention includes not only natural GPIb itself but also one in its amino acid sequence as long as the object of the present invention is achieved, as long as it has the binding ability to vWF.
- One or more amino acids with any mutation such as deletion, substitution, addition or modification, for example, a natural GPIb substitution, analog, mutant, modified, derivative, sugar chain adduct Etc. are also included.
- the GPIb ⁇ chain [His (1) to Leu (610)] a fragment of the vWF binding region of the light chain (hereinafter referred to as “GPIb light chain fragment”) and the like.
- examples of the substitute include a G Ib heavy chain fragment consisting of His (1) to A1a (302) in which G1y (233) or Met (239) is substituted with Va1.
- GPI b heavy chain fragments lack transmembrane sites.
- the transmembrane site is G In the PI b chain, Leu (486) to Gly (514) correspond (Proc. Nat 1. Acad. Sci. USA, 84, 5615 to 5619, published in 1987).
- the method for preparing GPIb is not particularly limited, and GPIb can be prepared by a method of extracting and isolating from platelet membrane, a method of cell culture, a method of producing by genetic engineering, and the like.
- Lipids that bind to GPIb via PAO have a functional group that can bind directly or indirectly to PAO.
- functional groups include an amino group (NH 2 group), a carboxyl group (COOH group), a thiol group (SH group), and an aldehyde group (CHO group), but are not particularly limited thereto. Any substance can be directly or indirectly bonded to PAO.
- lipid types include phospholipids, glycolipids, fatty acids, glycerides, and cholesterols. Preferably it is amphiphilic.
- lipids include phosphatidylethanolamine (hereinafter referred to as “PE”) and phosphatidylthioethanol (for example, 1,2-dioleoyl-1sn-glycerol-13-phosphatidylthioethanol and the like) in phospholipids.
- PPE phosphatidylethanolamine
- phosphatidylthioethanol for example, 1,2-dioleoyl-1sn-glycerol-13-phosphatidylthioethanol and the like
- Glycolipids include, for example, ceramide, cereproside, sphingosine, sulfatide, gangliosides, and glycerol glycolipids (eg, galactosyldiasylglycerol).
- Fatty acids include those having 12 to 18 carbon atoms, and may be saturated fatty acids or unsaturated fatty acids.
- palmitic acid, oleic acid and lauric acid are exemplified.
- glycerides include monoglyceride, diglyceride, and triglyceride.
- Cholesterols include cholesterol, cholesterol esters and arocholesterol.
- the functional groups in these lipids may be in the form of acid halides, acid anhydrides and active esters to enhance the reactivity with PA0 and the crosslinking agent described below.
- a cross-linking agent (so-called In addition, a product obtained by reacting a linker with a functional group of a lipid in advance can be used.
- a crosslinking agent include dicarboxylic acid, aminocarboxylic acid, bismaleimide compound, bishalocarbonyl compound, halocarbonylmaleide compound, dithiomaleimide, dithiocarboxylic acid, and maleimide carboxylic acid.
- These crosslinking agents preferably have 2 to 10 carbon atoms.
- the reaction between the crosslinking agent and the functional group of the lipid is carried out by a conventional means.
- PE-N-force luponylamine eg, PE-N-force prolylamine, PE-N-dodecanylamine, PE-N-glucurylamine, etc.
- PE-N-carbonyl for example, PE-N-succinyl, PE-N-glucuryl (NGP E), PE-N-dodecanyl (NDPE), etc.
- PE-N-dithioacylate for example, PE —N—3— (2-pyridyldithio) propionate, etc.
- PE—N—maleimidacylate eg, PE—N—4— (p-maleimidophenyl) butylate]
- PE—N-piotinyl and the like PE-N-force luponylamine (eg, PE-N-force prolylamine, PE-N-dodecanylamine, PE-N-glucurylamine, etc.)
- PE-N-carbonyl for example, PE
- PAO polyalkylene oxide
- PAO intervenes between (1) GPIb and (2) lipids and binds both.
- PAO has the same meaning as polyalkylene glycol, and examples include polyethylene glycol (PEG), polypropylene glycol, glycol obtained by copolymerizing ethylene oxide and propylene oxide, and the like.
- the number average molecular weight of PAO is from 100 to 100,000, preferably from 1,000 to 10,000.
- a crosslinking agent such as linker, linker
- examples of such a crosslinking agent include dicarboxylic acid, aminocarboxylic acid, bismaleimide compound, bishalocarbonyl compound, halocarbonylmaleimide compound, dithiomaleimide, dithiocarboxylic acid, maleimide carboxylic acid and the like.
- the reaction between these crosslinking agents and PAO is carried out by conventional means. 4
- the bond between GPIb and PAO and the bond between PAO and a lipid having a functional group can be chemically performed directly or indirectly, that is, without or through a group derived from a cross-linking agent. More preferred in the present invention is the mode of indirect binding.
- the mixing ratio of GPIb to PAO or a lipid having a functional group is about 1: 1 to 1:20, preferably about 1: 1 to 1:10 in molar ratio.
- Carbodimids eg, N, N, dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC), etc.
- EDC 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
- Succinimides eg, N-hydroxysuccinimide, N-hydroxysulfosuccinimide (NHSS), etc.
- those used in thiol group exchange reactions eg, 5, 5, -dithiobis (2 - nitrobenzoic acid), 2, 2 5 - dithio piston pyridine and the like] and the like.
- divalent crosslinking agent examples include a crosslinking agent having the same reactivity and a crosslinking agent having a different reactivity.
- examples of the same reactivity include dimethyl adipimidate and disuccinimidyl suberate, and examples of the different reactivity include succinimidyl 1-3- (2-pyridyldithio) propionate and N— (6-maleimidate). Docaproyloxy) succinimid, N-succinimidyl-16-maleimide hexanoate and the like.
- GPIb or lipid can be directly bonded to PAO by one COO— [for example, it can be obtained by ester bonding between the carboxyl group of GPlb or lipid (for example, fatty acid) and the hydroxyl group of PAO.
- N— for example, an aldehyde group in a sugar chain of GP lb
- a CH 2 NH— obtained by further reducing a Schiff bond
- a NH— etc., obtained by Schiff bonding of an aldehyde group introduced into a lipid and an amino group introduced into PAO.
- the mode of binding between the cross-linking agent (including a bivalent cross-linking agent; the same applies hereinafter) and PAO is the same as described above.
- —, — 0—, — CONH—, — CH N—, one CH 2 NH—, —NH one and the like.
- a crosslinker such as maleimide compound, halocarbonyl compound, etc.
- the preparation of the GP Ib-lipid conjugate may be performed in the presence of a surfactant.
- the surfactant is not particularly limited as long as it can solubilize lipids, but it is preferable to use a nonionic surfactant that does not affect the structure of GPIb.
- a nonionic surfactant that does not affect the structure of GPIb.
- those having a high critical micelle concentration (CMC) for example, those having a CMC of 1 mM or more are preferable.
- octyl glucoside for example, n-octyl /?-D-glucoside
- octyl thioglucoside for example, n-octyl-?-D-thioglucoside
- 31-((3-colamidopropyl) ) Dimethylammonio] propane sulfate (CHAPS) and N, N-bis (3-D-gluconamidopropyl) deoxycolamide deoxy-BIGCHAP.
- the mixing ratio of lipid: surfactant is preferably about 0.01: 1 to 0.1: 1 (molar ratio).
- Activated lipid consisting of PAO—lipid (hereinafter simply referred to as “activated lipid”)
- an activated lipid composed of a reactive substituent—PAO—lipid can be used as an intermediate for this purpose.
- the “activated lipid” refers to a conjugate of PAO and a lipid having a reactive substituent at the terminal of PAO.
- the PAO and the lipid are chemically linked, directly or indirectly, ie, without or via a group derived from the crosslinker.
- the reactive substituent is not particularly limited as long as it has an action of activating the binding to a protein. For example, it can be obtained by reacting succinimide, maleimide and the like with the PAO terminal.
- the reactive substituent in the activated lipid and the binding mode between PAO and PAO and the lipid are as described in the section on the preparation of the 4GPIb-lipid conjugate, respectively.
- activated lipid Chemically linking the activated lipid and GP lb, directly or indirectly, ie, with or without a cross-linking agent, results in a GPI b -lipid conjugate.
- the following compounds are specifically exemplified as the activated lipid.
- These activated lipids are known and can be produced according to known methods, and commercially available products can also be used.
- DSPE-34HCS I Distearoylphosphatidyl-N_ (succinimidylsuccinyl-polyoxyethylene-succinyl) ethanolamine.
- the number average molecular weight of PE G is 3400.
- DSPE-20HMAL Distearoylphosphatidyl-N- (maleimide propionylamino-polyoxyethylene-oxycarbonyl) ethanolamine.
- the number average molecular weight of PEG is 2000.
- the GPI b -lipid conjugate of the present invention has a molar ratio of GPI b to PAO or lipid of about 1: 1 to 1:20 in molar ratio.
- the composition ratio of PAO to lipid is 1: 1 in molar ratio.
- the complex of the present invention containing the above-described GPI b—lipid complex and free lipid is In the form of a solution, micelle, fat emulsion, etc., preferably in the form of ribosome Can be.
- a GPIb lipid complex in the form of ribosome will be described. The following description of the GPIb lipid complex applies to other forms besides liposomes.
- the lipid used here is not particularly limited as long as it can take the form of a lipid complex (for example, ribosome) either alone or as a mixture with another kind of lipid.
- examples of such lipids include phospholipids, glycolipids, cholesterols, fatty acids, and derivatives thereof.
- the free lipid for forming the complex any nontoxic lipid that is physiologically acceptable and can be metabolized can be used in the present invention.
- the free lipid means a lipid other than the lipid itself that constitutes the GP Ib-lipid conjugate, and may be any of the same type and different from the lipid that constitutes the GP Ib-lipid conjugate.
- phospholipid examples include phosphatidylcholine (hereinafter, referred to as “PC”), phosphatidylserine, phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, sphingomyelin, dicetylphosphate, cardiolipin, and lysophosphatidylcholine.
- PC phosphatidylcholine
- phosphatidylcholine hereinafter, referred to as “PC”)
- phosphatidylserine phosphatidic acid
- phosphatidylglycerol phosphatidylinositol
- sphingomyelin dicetylphosphate
- cardiolipin cardiolipin
- Fatty acids for example, those substituted with palmitic acid or myristic acid (diacylphosphatidylcholine, diacylphosphatidylglycerol, etc.) may be used.
- specific examples include purified egg yolk lecithin, hydrogenated purified soybean lecithin, egg yolk-derived phosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, distearylphosphatidylcholine, and dimyristylphosphatidylcholine.
- glycolipids examples include ceramide, celeb mouth side, sphingosine, sulfatide, gangliosides, and glycerol side glycolipids.
- Cholesterols include cholesterol, cholesterol esters, Contains sterols.
- Fatty acids include, for example, oleic acid, lauric acid, myristic acid, palmitic acid and stearic acid.
- lipid derivatives include phosphatidylethanolamine and polyoxyethylene derivatives of fatty acids, and polysaccharide derivatives of fatty acids and cholesterol.
- the mixing ratio of GPIb—lipid conjugate: free lipid is such that the molar ratio of GPIb to free lipid is about 1:10 to 1: 1000, preferably 1:50 to 1: 2. It is about 00.
- GP lb lipid complexes can be prepared by, for example, detergent removal, hydration, ultrasonication, reversed-phase distillation, freeze-thaw, ethanol injection, and extrusion (extrusion). on method) and a high-pressure emulsification method. Gel filtration, dialysis, ultrafiltration and the like are generally used as a surfactant removing method.
- a method of binding GPIb to lipid via PAO and then forming a complex that is, a method of preparing a GPIb-lipid conjugate and then forming a lipid complex is more preferable.
- lipid complex for example, ribosome
- GP lb is added, and the lipid of (I) 2 and GP Ib
- Isolation and purification of the GP Ib lipid complex can be performed by a means known per se such as centrifugation and gel filtration.
- the conjugate of lipid [(I) 2] with PAO and GPIb were mixed in the presence of a surfactant to prepare a GPIb-lipid conjugate, and then free lipid [(II ) 1] may be mixed to form a GPIb lipid complex by a method of removing the surfactant. Unreacted GPIb, lipid [(1) ⁇ ], free lipid [(II) 1], etc. are separated and removed to obtain a purified product.
- the definition of the surfactant is as defined above.
- the mixing ratio is as follows: free fat [(II) 1]: 0.001::! ⁇ 0.1: 1 (molar ratio).
- lipid [(1) 2] and PAO and free lipid [(II) 1] Dissolve the combined product of lipid [(1) 2] and PAO and free lipid [(II) 1] in an organic solvent such as chloroform, ethanol, etc., remove the organic solvent after mixing.
- organic solvent such as chloroform, ethanol, etc.
- An appropriate aqueous solvent is added, and a lipid complex is formed by a known method such as shaking or stirring.
- GPIb is added to bind GPIb and lipid via PAO to form a GPIb lipid complex. Unreacted GPIb, lipids, etc. are separated and removed to obtain a purified product.
- free lipid [(II) I] that does not react with or bind to GPIb is used.
- Specific examples include phosphatidylcholine and lysophosphatidylcholine.
- the ratio of GPIb to free lipid [(II) 1] in the obtained GPIb lipid complex was 0.01 to 10 parts by weight per 1 part by weight of free lipid [(11) 1]. And preferably 0.1 to 5 parts by weight.
- the particle size of the obtained GPI b lipid complex is about 50-500 nm, preferably about 100-400 nm.
- the number of GP I b molecules per particle is 100 to 1 0000, preferably 250 to 3000, the surface density of 10 10 to 10 13 of GPI b, preferably 10 "to 10 12.
- Examples of the structure of the GPlb lipid complex include a multilamellar vesicle (MLV), a small unilamellar vesicle, a large nilamellar vesicle, and the like. Further, it may be coated with a hydrophilic polymer (derivative) such as polyethylene glycol (PEG) or Pull Mouth Nick (registered trademark) (polyoxyethylene polyoxypropylene block copolymer).
- MMV multilamellar vesicle
- PEG polyethylene glycol
- Pull Mouth Nick registered trademark
- the obtained GPIb lipid complex is then washed, if necessary, with a physiologically acceptable aqueous solution, sterilized by filtration, and dispensed to prepare a liquid preparation, a pellet form, and a suspension form. .
- Formulation is in accordance with widely known methods in the production of pharmaceuticals.
- the preparation is also provided as a lyophilized preparation by freezing the liquid preparation and drying it under reduced pressure.
- monosaccharides eg, glucose, etc.
- disaccharides eg, sucrose, etc.
- the preparation of the GPIb lipid complex may contain as a stabilizer a polymer selected from albumin, dextran, vinyl polymer, gelatin and hydroxylethyl starch.
- the macromolecular substance may be incorporated into the voids in the lipid complex together with the drug, or may be added to and blended with the preparation of the lipid complex incorporating the drug (ie, added and blended outside the liposome). Is also good. It goes without saying that both the inside and outside of the lipid complex may be blended.
- the amount of the stabilizer to be added is 0.5 to 10 parts by weight, preferably 1 to 5 parts by weight, per 1 part by weight of the free lipid [(II) 1].
- the GPI b lipid complex of the present invention can be used as a diagnostic agent for vascular injury sites, thrombus formation sites, von Willebrand factor deficiency, etc. .
- labeling substances include RI (radioactive Radioisotopes), paramagnetic metals for MR I, iodine compounds for X-ray imaging, fluorescent substances and dyes.
- the RI for example, 3 H, 14 C, 99m Tc, 123 1, 125 1, 131 1, 871 S r s 113a I n and 197 Hg and the like.
- paramagnetic metals for MR I include chromium (Cr) -gadolinium (Gd), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), and brassodime (Pr). , Neodymium (Nd), samarium (Sm), ytterbium (Yb), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er) and copper (Cu). Examples thereof include divalent or trivalent ions, and among them, preferred are divalent or trivalent ions such as gadolinium, terpium, dysprosium, holmium, erbium, and iron.
- a compound known as a known X-ray contrast agent can be used as the iodine compound for X-ray contrast.
- adipiodone, amidotrizoic acid, iodaramic acid, iopanoic acid, thiopenzamic acid, iobodate, tylopanoic acid, thiopidol, iopidone, propriodone, iodamide or a salt thereof (eg, sodium salt, meglumine salt, etc.) are exemplified. Is done.
- the fluorescent substance include fluorescein isothiocyanate (FITC) and carboxyfluorescein (CF).
- labeling substances can be encapsulated in a lipid complex (for example, ribosome) by a known method.
- a chelating agent such as a salt form or a chelating agent such as ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminopentaacetic acid (DTPA) and encapsulated in a lipid complex.
- EDTA ethylenediaminetetraacetic acid
- DTPA diethylenetriaminopentaacetic acid
- the agent for testing or diagnosis of the present invention containing the labeling substance and the GPIb lipid complex can be prepared by the same method as described above using GPIb labeled with a labeling substance (for example, RI).
- a GPI b lipid complex of the invention may be prepared. Since the GPI b lipid complex of the present invention has a property of accumulating at the site of vascular injury, An embodiment as a containing composition (drug carrier) can also be taken.
- a drug is not particularly limited as long as it is physiologically and pharmacologically effective by accumulating at the site of vascular injury. Examples thereof include a hemostatic agent, a vasoconstrictor, an anti-inflammatory agent, Thrombolytic agents, anticoagulants, antiplatelet agents and the like.
- Hemostatic agents include carbazochrome, blood coagulation factors (FVIII, FIX), thrombin, antiplasmin agents (eg, epsilon-monoaminocaproic acid, tranexamic acid), prominamine sulfate, ethanesylate, phytonadione and conjugated estrogens (eg, , Sodium estrone sulfate, sodium equilin sulfate) and the like.
- FVIII, FIX blood coagulation factors
- thrombin eg, epsilon-monoaminocaproic acid, tranexamic acid
- antiplasmin agents eg, epsilon-monoaminocaproic acid, tranexamic acid
- prominamine sulfate ethanesylate
- phytonadione and conjugated estrogens eg, Sodium estrone sulfate, sodium equilin sulf
- vasoconstrictor noradrenaline, Norufuenefurin, phenylene Refurin, main evening lamino Ichiru, main Tokisamin, prostaglandins shed, like prostaglandin F 2 Hioyobi thromboxane A 2 are exemplified.
- anti-inflammatory drugs examples include steroid-based anti-inflammatory drugs (dexamethasone, hydrocortisone, prednisolone, vesamethasone, triamcinolone, methylprednisolone, etc.), non-steroid anti-inflammatory drugs (indamesin, asemesin, Flurbiprofen, aspirin, ibuprofen, flufenamic acid, ketoprofen, etc.).
- steroid-based anti-inflammatory drugs diamethasone, hydrocortisone, prednisolone, vesamethasone, triamcinolone, methylprednisolone, etc.
- non-steroid anti-inflammatory drugs indamesin, asemesin, Flurbiprofen, aspirin, ibuprofen, flufenamic acid, ketoprofen, etc.
- thrombolytic agent examples include plasmin, tissue plasminogen, perkinase, etc., or precursors and derivatives thereof.
- anticoagulant examples include acidic mucopolysaccharides such as heparin, coumarin anticoagulants, natural extracts such as hirudin and derivatives thereof, and physiologically active substances such as thrombomodulin-active protein C.
- antiplatelet agent examples include aspirin, ticlovidine, syrosyl sol, prosyl cyclin and the like. These drugs are encapsulated in a lipid complex by a known method.
- the GPIb lipid complex of the present invention can be administered as GPIb at a rate of about 0.001 to 100 Omg per day.
- the dose can be appropriately adjusted according to the sex, age, symptoms, etc. of the patient.
- the GPI b lipid complex of the present invention is more preferably administered parenterally.
- Concrete Specific examples include intravascular (intra-arterial, intravenous) injection, continuous infusion, subcutaneous administration, local administration, or intramuscular administration.
- compositions containing the GPIb lipid complex of the present invention include platelet substitutes, drugs for preventing and treating vascular disorders, vascular damage, thrombosis, etc., and diagnostic agents for diagnosing vWF deficiency, etc. , Biological and medical reagents, platelet aggregation inhibitors, and antithrombotic screening reagents. It is also useful as a diagnostic or therapeutic agent for examining sites of vascular injury and thrombus formation.
- the GPIb used in Examples and Experimental Examples of the present invention is a GPIb heavy chain fragment (His (1) -Arg (293), molecular weight 45000) produced by genetic engineering using CHO cells. And Japanese Patent Application Laid-Open No. 9-208599].
- EPC yolk phosphatidylcholine
- 45.4 mg of cholesterol 2.33 g of octylglucoside (0G)
- the amount of EPC corresponds to 100 times the molar ratio of GPIb.
- a solution obtained by dissolving DSPE-34HC SI purchased from NOF Corporation
- HEPE S (pH 8.0) buffer containing 0.1% 0G was added.
- the amount of DSPE-34HCS I added was 10 times the molar amount of GP Ib.
- ribosomes were collected by centrifugation using the CsC1 density gradient method.
- the conditions are as follows. That is, CsCl was dissolved in 1 to 1.5 mL of the sample to a 35% concentration, and 0.5 mL of 25% CsC1 and 0.1 mL of saline solution were overlaid, and 214,000 Xg for 10 minutes Processed.
- the ribosome-containing fraction was collected and dialyzed into a dialysis membrane (fraction molecular weight 10,000 daltons, Slide-A-Lyzer 10 (K, manufactured by Pierce) overnight.
- the prepared GP Ib ribosome had a PC concentration of 0.61 mg / mL, a GP Ib concentration of 0.24 mg / mL, and an average particle size of 0.25 / m.
- the solution (100 mg / mL) was added in an amount of 100 ⁇ L, and reacted at room temperature for 10 minutes. Further, 25 mM NaI was added at 100 / L, and the solution was subjected to gel filtration (MicroSpInG-25, manufactured by Pharmacia Biotech) and ultrafiltration (U1trafree_MC 10K, manufactured by Millipore). Iodine-labeled GP Ib ( 125 I—GP Ib) was prepared.
- Example 2 All operations were performed in the same manner as in Example 1 except that the above 125 I-GPIb was used instead of GPIb in Example 1.
- the PC concentration of the prepared GP I b ribosome is 3.54 mg / mL, 0-1) 3 concentration is 1.00 mg / mL, average particle size is 0.33 ⁇ m, radioactivity is 9.3 X 10 7 cpm / mL.
- the aggregation ability of GP Ib ribosome was confirmed.
- the GPIb ribosome prepared in Example 1 was adjusted to a PC concentration of 0.2 mgZmL.
- 25 ⁇ L of a 2 mg / mL vWF solution was added, and the mixture was stirred and stirred at 37 ° C.
- 25 ⁇ L of a 15 mg / mL ristocetin solution was mixed.
- Aggregates were measured using a platelet aggregometer (AG-10, manufactured by Kowa Co., Ltd.) for a total of 15 minutes immediately before the incubation. The sum of the number of aggregates multiplied by the scattering intensity was calculated and used as an index of the degree of aggregate formation. Table 1 shows the results.
- the GPI b ribosome according to the present invention specifically reacted with vWF in the presence of ristocetin to form an aggregate. This proved that the GPI b ribosome was useful as a platelet substitute. It was also found that the GPI b ribosome according to the present invention had improved aggregation ability as compared with the control product.
- the blood kinetics of GP I b ribosome was confirmed.
- the iodine-labeled GPI b ribosome prepared in Example 2 was administered to a Hart 1 ey guinea pig (Example 3) into the femoral vein at a dose of 1 mg / kg body weight as GPIb. Blood was collected from the orbit over time up to 60 minutes after administration, and 100 / L of the blood was counted (1 minute) with a gamma-one count.
- a similar experiment was carried out using GPI b ribosome not described in Example 1 of JP-A-9-208599, without using PEG. Table 3 shows the results. Table 3
- the GPI b ribosome according to the present invention has improved retention in blood as compared to the control product.
- the GPI b lipid complex of the present invention can bind to vWF and form aggregates. Therefore, platelet substitutes, drugs for the prevention and treatment of vascular disorders, vascular damage and thrombosis, etc., or diagnostic agents for diagnosing vWF deficiency, biological and medical reagents, platelet aggregation Inhibitors ⁇ It is expected to have a wide range of practical applications as a screening reagent for antithrombotic agents.
- the GPIb lipid complex of the present invention has a property of specifically accumulating at a vascular injury site, it is extremely useful as a diagnostic or therapeutic agent for testing a vascular injury site and a thrombus formation site. Further, the GPI b lipid complex of the present invention has excellent retention in blood, and can exhibit sustained pharmacological action.
- the GPIB-lipid conjugate of the present invention is highly useful as an active ingredient of the GPIB lipid complex of the present invention.
- This application is based on a patent application No. 2000-570449 filed in Japan, the contents of which are incorporated in full herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60130741T DE60130741T2 (de) | 2000-03-02 | 2001-03-02 | GPib-GEBUNDENES KONSTRUKT UND VERWENDUNGEN DAVON |
AU2001236062A AU2001236062A1 (en) | 2000-03-02 | 2001-03-02 | Gpib-lipid bond construct and use thereof |
US10/220,610 US6926884B2 (en) | 2000-03-02 | 2001-03-02 | GPIb-lipid bond construct and use thereof |
EP01908262A EP1262490B1 (en) | 2000-03-02 | 2001-03-02 | GPib-LIPID BOND CONSTRUCT AND USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000057449 | 2000-03-02 | ||
JP2000-57449 | 2000-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001064743A1 true WO2001064743A1 (fr) | 2001-09-07 |
Family
ID=18578236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/001635 WO2001064743A1 (fr) | 2000-03-02 | 2001-03-02 | CONSTRUCTION A LIAISON GPib-LIPIDE ET UTILISATION CORRESPONDANTE |
Country Status (7)
Country | Link |
---|---|
US (1) | US6926884B2 (ja) |
EP (1) | EP1262490B1 (ja) |
AT (1) | ATE374785T1 (ja) |
AU (1) | AU2001236062A1 (ja) |
DE (1) | DE60130741T2 (ja) |
ES (1) | ES2291295T3 (ja) |
WO (1) | WO2001064743A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004045583A1 (ja) * | 2002-11-15 | 2004-06-03 | Nipro Corporation | リポソーム |
JP2006510396A (ja) * | 2002-10-21 | 2006-03-30 | アルヴィヴォ インコーポレイテッド | 生物活性化合物を含む表面コーティング |
WO2007077990A1 (ja) | 2006-01-06 | 2007-07-12 | Keio University | 薬物運搬体 |
JP2007204469A (ja) * | 2006-01-06 | 2007-08-16 | Keio Gijuku | 薬物運搬体 |
WO2020080496A1 (ja) | 2018-10-17 | 2020-04-23 | 東レ株式会社 | 止血材 |
WO2020080495A1 (ja) | 2018-10-17 | 2020-04-23 | 東レ株式会社 | カルボン酸型脂質並びに該カルボン酸型脂質を含んでなる脂質粒子及び脂質膜 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1173600A2 (en) * | 1999-04-20 | 2002-01-23 | The University Of British Columbia | Cationic peg-lipids and methods of use |
KR20050111583A (ko) * | 2003-02-06 | 2005-11-25 | 각고호우징 게이오기주크 | 펩티드 결합체 |
JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20080015145A1 (en) * | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
CA2600220C (en) * | 2006-09-07 | 2014-12-09 | Canadian Blood Services | Surface cross-linked lipidic particles, methods of production and uses therefor |
US20080241233A1 (en) * | 2007-03-28 | 2008-10-02 | Portola Pharmaceuticals, Inc. | Targeted delivery and expression of procoagulant hemostatic activity |
JP2020500020A (ja) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | 融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0894807A1 (en) * | 1996-02-07 | 1999-02-03 | Yoshitomi Pharmaceutical Industries, Ltd. | GPIb-LIPID COMPLEX AND USES THEREOF |
WO1999058694A1 (en) * | 1998-05-12 | 1999-11-18 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200510A (en) | 1987-06-16 | 1993-04-06 | Zymogenetics, Inc. | Method for purifying factor viii:c, von willebrand factor and complexes thereof |
US5340727A (en) | 1987-11-17 | 1994-08-23 | The Scripps Research Institute | GPIbα fragments and recombinant DNA expression vectors |
EP0787201B1 (en) * | 1995-08-17 | 2004-04-28 | Crucell Holland B.V. | Poly(organo)phosphazenes for use in synthetic transfection systems |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
-
2001
- 2001-03-02 AT AT01908262T patent/ATE374785T1/de not_active IP Right Cessation
- 2001-03-02 DE DE60130741T patent/DE60130741T2/de not_active Expired - Lifetime
- 2001-03-02 WO PCT/JP2001/001635 patent/WO2001064743A1/ja active IP Right Grant
- 2001-03-02 ES ES01908262T patent/ES2291295T3/es not_active Expired - Lifetime
- 2001-03-02 US US10/220,610 patent/US6926884B2/en not_active Expired - Fee Related
- 2001-03-02 EP EP01908262A patent/EP1262490B1/en not_active Expired - Lifetime
- 2001-03-02 AU AU2001236062A patent/AU2001236062A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0894807A1 (en) * | 1996-02-07 | 1999-02-03 | Yoshitomi Pharmaceutical Industries, Ltd. | GPIb-LIPID COMPLEX AND USES THEREOF |
WO1999058694A1 (en) * | 1998-05-12 | 1999-11-18 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
Non-Patent Citations (3)
Title |
---|
WEBB M.S. ET AL.: "Comparison of different hydrophobic anchors conjugated to poly (ethylene glycol): effects on the pharmacokinetics of liposomal vincristine", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1372, no. 2, 1998, pages 272 - 282, XP002942110 * |
ZALIPSKY S. ET AL.: "Poly (ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains", BIOCONJUGATE CHEMISTRY, vol. 8, no. 2, 1997, pages 111 - 118, XP002942108 * |
ZALIPSKY S. ET AL.: "Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes", BIOCONJUGATE CHEMISTRY, vol. 4, no. 4, 1993, pages 296 - 299, XP002942109 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006510396A (ja) * | 2002-10-21 | 2006-03-30 | アルヴィヴォ インコーポレイテッド | 生物活性化合物を含む表面コーティング |
WO2004045583A1 (ja) * | 2002-11-15 | 2004-06-03 | Nipro Corporation | リポソーム |
JPWO2004045583A1 (ja) * | 2002-11-15 | 2006-03-16 | ニプロ株式会社 | リポソーム |
JP4848637B2 (ja) * | 2002-11-15 | 2011-12-28 | ニプロ株式会社 | リポソーム |
WO2007077990A1 (ja) | 2006-01-06 | 2007-07-12 | Keio University | 薬物運搬体 |
JP2007204469A (ja) * | 2006-01-06 | 2007-08-16 | Keio Gijuku | 薬物運搬体 |
WO2020080496A1 (ja) | 2018-10-17 | 2020-04-23 | 東レ株式会社 | 止血材 |
WO2020080495A1 (ja) | 2018-10-17 | 2020-04-23 | 東レ株式会社 | カルボン酸型脂質並びに該カルボン酸型脂質を含んでなる脂質粒子及び脂質膜 |
Also Published As
Publication number | Publication date |
---|---|
DE60130741D1 (de) | 2007-11-15 |
AU2001236062A1 (en) | 2001-09-12 |
EP1262490A1 (en) | 2002-12-04 |
EP1262490B1 (en) | 2007-10-03 |
US6926884B2 (en) | 2005-08-09 |
ES2291295T3 (es) | 2008-03-01 |
DE60130741T2 (de) | 2008-07-03 |
US20030113262A1 (en) | 2003-06-19 |
ATE374785T1 (de) | 2007-10-15 |
EP1262490A4 (en) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3735921B2 (ja) | GPIb・脂質複合体およびその用途 | |
AU710837B2 (en) | Site specific binding system, imaging compositions and methods | |
AU2004264857B2 (en) | Remote detection of substance delivery to cells | |
JP4332507B2 (ja) | 医薬組成物 | |
US20030133972A1 (en) | Targeted multivalent macromolecules | |
US5851536A (en) | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures | |
WO2001064743A1 (fr) | CONSTRUCTION A LIAISON GPib-LIPIDE ET UTILISATION CORRESPONDANTE | |
CZ20023913A3 (cs) | Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy | |
US5366958A (en) | Localized delivery using fibronectin conjugates | |
de Lima et al. | Liposome surface modification by phospholipid chemical reactions | |
WO2000071172A1 (en) | Site specific binding system, nuclear imaging compositions and methods | |
JP2009280625A (ja) | 増強された結合特性を有する診断および治療のための多成分集合体 | |
WO1993020802A1 (en) | Acoustically reflective liposomes and methods to make and use the same | |
JPH10507172A (ja) | リポソーム剤 | |
US7887837B2 (en) | Drug delivery material | |
EP1401818A2 (en) | Targeted multivalent macromolecules | |
US20050058697A1 (en) | Cell penetrating therapeutic agents | |
JP2020183446A (ja) | Peg化リポソームおよび血液凝固因子の製剤処方 | |
JP2006514924A (ja) | 走触性ペプチドを含むリポソーム組成物及びその使用 | |
AU771565B2 (en) | Site specific binding system, nuclear imaging compositions and methods | |
AU2004202725A1 (en) | Site specific binding system, nuclear imaging compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 564236 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001908262 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10220610 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001908262 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001908262 Country of ref document: EP |